搜索
 > 【MS4A1】

MS4A1信息

英文名称:B-lymphocyte antigen CD20
中文名称:B淋巴细胞抗原CD20
靶点别称:CD20,MS4A1,Membrane-spanning 4-domains subfamily A member 1,CD_antigen=CD20,B-lymphocyte antigen CD20,Leukocyte surface antigen Leu-16,Bp35,B-lymphocyte surface antigen B1
上市药物数量:21
临床药物数量:100
最高研发阶段:批准上市

MS4A1产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
 
评论(0)
 

MS4A1 分子别名

MS4A1,CD20,MS4A-1

MS4A1 分子背景

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

MS4A1 前沿进展

MS4A1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

MS4A1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定